179 related articles for article (PubMed ID: 29435174)
21. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
23. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
24. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
[TBL] [Abstract][Full Text] [Related]
25. Expression of cyclin-dependent kinases and their clinical significance with immune infiltrates could predict prognosis in colorectal cancer.
Fadaka AO; Samantha Sibuyi NR; Bakare OO; Klein A; Madiehe AM; Meyer M
Biotechnol Rep (Amst); 2021 Mar; 29():e00602. PubMed ID: 33732631
[TBL] [Abstract][Full Text] [Related]
26. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
Pan MH; Chen WJ; Lin-Shiau SY; Ho CT; Lin JK
Carcinogenesis; 2002 Oct; 23(10):1677-84. PubMed ID: 12376477
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cyclin-dependent kinases by p21.
Harper JW; Elledge SJ; Keyomarsi K; Dynlacht B; Tsai LH; Zhang P; Dobrowolski S; Bai C; Connell-Crowley L; Swindell E
Mol Biol Cell; 1995 Apr; 6(4):387-400. PubMed ID: 7626805
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
29. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
Ahmad N; Adhami VM; Afaq F; Feyes DK; Mukhtar H
Clin Cancer Res; 2001 May; 7(5):1466-73. PubMed ID: 11350919
[TBL] [Abstract][Full Text] [Related]
30. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
Schmid G; Strosznajder JB; Wesierska-Gadek J
Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
[TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
32. CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
Zabihi M; Safaroghli-Azar A; Gharehbaghian A; Allahbakhshian Farsani M; Bashash D
Iran J Pharm Res; 2019; 18(Suppl1):119-131. PubMed ID: 32802093
[TBL] [Abstract][Full Text] [Related]
33. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation.
Poon RY; Toyoshima H; Hunter T
Mol Biol Cell; 1995 Sep; 6(9):1197-213. PubMed ID: 8534916
[TBL] [Abstract][Full Text] [Related]
34. Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519.
Karaś K; Karwaciak I; Chałaśkiewicz K; Sałkowska A; Pastwińska J; Bachorz RA; Ratajewski M
Biomed Pharmacother; 2023 Aug; 164():115002. PubMed ID: 37311277
[TBL] [Abstract][Full Text] [Related]
35. Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
Ruiz de Porras V; Bystrup S; Cabrero-de Las Heras S; Musulén E; Palomero L; Alonso MH; Nieto R; Arango D; Moreno V; Queralt C; Manzano JL; Layos L; Bugés C; Martinez-Balibrea E
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614664
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
37. Identification of ribosomal protein L34 as a novel Cdk5 inhibitor.
Moorthamer M; Chaudhuri B
Biochem Biophys Res Commun; 1999 Feb; 255(3):631-8. PubMed ID: 10049762
[TBL] [Abstract][Full Text] [Related]
38. Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth
Yin F; Zhao R; Gorja DR; Fu X; Lu N; Huang H; Xu B; Chen H; Shim JH; Liu K; Li Z; Laster KV; Dong Z; Lee MH
Acta Pharm Sin B; 2022 Nov; 12(11):4122-4137. PubMed ID: 36386480
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
40. CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.
Ianes C; Xu P; Werz N; Meng Z; Henne-Bruns D; Bischof J; Knippschild U
Amino Acids; 2016 Feb; 48(2):579-92. PubMed ID: 26464264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
